Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2018

Publisher Name :
Date: 12-Jun-2018
No. of pages: 91
Inquire Before Buying

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2018, provides an overview of the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline landscape.

Hereditary angioedema (HAE) is a rare inherited disease that causes considerable swelling in various body tissues, such as the abdomen or face. Symptoms include severe abdominal pain and cramping, dehydration, diarrhea and shock, hoarse voice, difficulty swallowing and difficulty breathing. Treatment includes medications, such as epinephrine, antihistamines, and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I, Preclinical and Discovery stages are 4, 1, 5, 9 and 1 respectively.

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology).

- The pipeline guide reviews pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Overview
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Companies Involved in Therapeutics Development
Adverum Biotechnologies Inc
BioCryst Pharmaceuticals Inc
Cevec Pharmaceuticals GmbH
CSL Ltd
iBio Inc
Ionis Pharmaceuticals Inc
Kalvista Pharmaceuticals Inc
Pharming Group NV
ProMetic Life Sciences Inc
Rezolute Inc
Shire Plc
Verseon Corp
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Drug Profiles
ADVM-053 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATN-035 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATN-249 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCX-7353 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C1 esterase inhibitor (recombinant) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C1 esterase inhibitor (recombinant) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C1-esterase inhibitor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSL-312 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
icatibant acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-PKKLRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-PKKRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KVD-818 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KVD-900 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KVD-XXX - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanadelumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RZ-602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant Projects
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Discontinued Products
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Product Development Milestones
Featured News & Press Releases
May 29, 2018: BioCryst Announces Presentation of Additional Analyses of the APeX-1 Clinical Trial of BCX7353 at the 2018 European Academy of Allergy and Clinical Immunology (EAACI) Congress
May 29, 2018: KalVista Pharmaceuticals Presents Data at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018
May 24, 2018: BioCryst's BCX7353 Receives European Regulatory Designations for the Treatment of Hereditary Angioedema
Apr 18, 2018: The Swiss Agency for Therapeutic Products (Swissmedic) Validates Shire's Marketing Authorization Application for Investigational Hereditary Angioedema Treatment Lanadelumab
Mar 29, 2018: Shire Reports Regulatory Milestones for Investigational Hereditary Angioedema Treatment Lanadelumab
Mar 15, 2018: BioCryst Announces Initiation of the Phase 3 APeX-2 Trial of BCX7353 in Patients with Hereditary Angioedema
Mar 15, 2018: CSL Behring Receives Patient Impact Award For Subcutaneous Prophylactic Treatment To Prevent Hereditary Angioedema Attacks
Mar 03, 2018: New Data from Pivotal Phase 3 Study Investigating Lanadelumab as a Prophylactic Treatment for Hereditary Angioedema to be Presented at 2018 AAAAI/WAO Joint Congress
Feb 28, 2018: BioCryst Announces Initiation of the APeX-S Long-Term Safety Trial of BCX7353 in Patients with Hereditary Angioedema
Feb 27, 2018: The European Medicines Agency Grants Accelerated Assessment for Shire's Lanadelumab Being Evaluated for the Prevention of Attacks in Hereditary Angioedema Patients Aged 12 Years and Older
Feb 23, 2018: FDA Accepts Shire Biologics License Application (BLA) and Grants Priority Review for Lanadelumab for the Prevention of Attacks in Hereditary Angioedema (HAE) Patients
Feb 15, 2018: Shire Announces FDA Acceptance of sBLA for CINRYZE (C1 esterase inhibitor [human]) for Pediatric Hereditary Angioedema Use
Feb 13, 2018: Shire Provides Regulatory Progress Update On Lanadelumab
Jan 17, 2018: Pharming announces FDA Acceptance for Review of Supplemental Biologics License Application for RUCONEST for Prophylaxis of Hereditary Angioedema Attacks
Jan 10, 2018: Verseon presents hereditary angioedema program at Biotech Showcase
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Adverum Biotechnologies Inc, H1 2018
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by BioCryst Pharmaceuticals Inc, H1 2018
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Cevec Pharmaceuticals GmbH, H1 2018
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by CSL Ltd, H1 2018
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by iBio Inc, H1 2018
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Ionis Pharmaceuticals Inc, H1 2018
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Kalvista Pharmaceuticals Inc, H1 2018
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Pharming Group NV, H1 2018
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by ProMetic Life Sciences Inc, H1 2018
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Rezolute Inc, H1 2018
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Shire Plc, H1 2018
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Verseon Corp, H1 2018
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant Projects, H1 2018
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Discontinued Products, H1 2018

List of Figures
Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  • 2018-2023 Global PEGylated Proteins Consumption Market Report
    Published: 15-Jun-2018        Price: US 4660 Onwards        Pages: 138
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global PEGylated Proteins market for 2018-2023. PEGylating has been widely used as a post-production modification methodology for improving biomedical efficacy and physicochemical properties of therapeutic proteins since the first PEGylated product was approved by Food and Drug Administration in the early 1990s. The threat of substitutes arises when there a......
  • 2018 Top 5 PEGylated Proteins Players in North America, Europe, Asia-Pacific, South America, Middle East and Africa
    Published: 15-Jun-2018        Price: US 4960 Onwards        Pages: 125
    PEGylating has been widely used as a post-production modification methodology for improving biomedical efficacy and physicochemical properties of therapeutic proteins since the first PEGylated product was approved by Food and Drug Administration in the early 1990s. The threat of substitutes arises when there are similar products developed by competitors which satisfy the market needs. When consumers have access to substitute products which can satisfy their market needs, then manufacturer......
  • 2018-2023 Global Erythropoietin Consumption Market Report
    Published: 15-Jun-2018        Price: US 4660 Onwards        Pages: 131
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Erythropoietin market for 2018-2023. Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adult......
  • 2018 Top 5 Erythropoietin Players in North America, Europe, Asia-Pacific, South America, Middle East and Africa
    Published: 15-Jun-2018        Price: US 4960 Onwards        Pages: 125
    Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood. Erythropoietin is an essential hormone for red blood cell production. Without it, definitive erythropoiesis does not take place. Under hypoxic conditions, t......
  • Global Enzymatic Debridement Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 15-Jun-2018        Price: US 3480 Onwards        Pages: 129
    Enzymatic Debridement uses chemical enzymes to assist in wound healing. Enzymes that help slough off the dead tissue are often available as part of a topic ointment; however, the ointment must be carefully applied to only the currently dead tissue - if the enzymes come in contact with healthy tissue, they could cause issues. Scope of the Report: This report focuses on the Enzymatic Debridement in global market, especially in North America, Europe and Asia-Pacific, South Ame......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Enzymatic Debridement Market 2018, Forecast to 2023
    Published: 15-Jun-2018        Price: US 4880 Onwards        Pages: 133
    Enzymatic Debridement uses chemical enzymes to assist in wound healing. Enzymes that help slough off the dead tissue are often available as part of a topic ointment; however, the ointment must be carefully applied to only the currently dead tissue - if the enzymes come in contact with healthy tissue, they could cause issues. Scope of the Report: This report focuses on the Enzymatic Debridement in global market, especially in North America, Europe and Asia-Pacific, South Ame......
  • Global Vaccine Market, People Vaccinated, Administered, Immunization, By Disease, By End User, Companies
    Published: 14-Jun-2018        Price: US 1990 Onwards        Pages: 355
    Global Vaccine Market is projected to reach US$ 70 Billion by the year 2024. The vaccine market is likely to witness a significant growth throughout the forecast period due to the growing prevalence of diseases, increasing government and non-government funding for vaccine development & distribution and increasing investments by companies to develop new vaccines. Furthermore, growing demand for preventive vaccines, rising consciousness about vaccination coupled with mounting demand from th......
  • Global Celery Seed Extract Solid Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 13-Jun-2018        Price: US 3480 Onwards        Pages: 135
    Celery seed solid extract and oil are majorly used for healthcare benefits as anti-spasmodic, nerve stimulant, stimulant and tonic in asthma, rheumatoid arthritis, intestinal antiseptic. The essential oil of celery seed comprise of sesquiterpene alcohols, sedanolide, d-limonene, selinene, and sedanonic anhydride. Celery oil is mostly used for flavoring of food and perfumes. Scope of the Report: This report focuses on the Celery Seed Extract Solid in global market, especial......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Celery Seed Extract Solid Market 2018, Forecast to 2023
    Published: 13-Jun-2018        Price: US 4880 Onwards        Pages: 128
    Celery seed solid extract and oil are majorly used for healthcare benefits as anti-spasmodic, nerve stimulant, stimulant and tonic in asthma, rheumatoid arthritis, intestinal antiseptic. The essential oil of celery seed comprise of sesquiterpene alcohols, sedanolide, d-limonene, selinene, and sedanonic anhydride. Celery oil is mostly used for flavoring of food and perfumes. Scope of the Report: This report focuses on the Celery Seed Extract Solid in global market, especial......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs